Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19

NCT04928430 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

290

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of recruitment

Conditions

COVID-19

Interventions

DRUG: XAV-19
DRUG: Placebo

Sponsor

Xenothera SAS